Last reviewed · How we verify
Glipizide and Glargine
Glipizide stimulates insulin secretion from pancreatic beta cells, while glargine provides long-acting basal insulin replacement to lower blood glucose.
Glipizide stimulates insulin secretion from pancreatic beta cells, while glargine provides long-acting basal insulin replacement to lower blood glucose. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Glipizide and Glargine |
|---|---|
| Also known as | Insulin Lantus |
| Sponsor | Cook County Health |
| Drug class | Insulin secretagogue + Long-acting insulin |
| Target | ATP-sensitive potassium channel (glipizide); Insulin receptor (glargine) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Glipizide is a meglitinide that binds to ATP-sensitive potassium channels on beta cells, triggering insulin release in response to glucose. Glargine is a long-acting insulin analog that provides steady, basal insulin coverage over 24 hours. Together, they address both postprandial and fasting hyperglycemia in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Headache
- Dizziness
- Injection site reactions (glargine)
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
- A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019) (PHASE3)
- Insulin Glargine in Type 2 Diabetic Patients (PHASE4)
- Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glipizide and Glargine CI brief — competitive landscape report
- Glipizide and Glargine updates RSS · CI watch RSS
- Cook County Health portfolio CI